27th Aug 2024 14:17
27 August 2024
Belluscura plc
("Belluscura" or the "Company")
Result of General Meeting
Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that at the Annual General Meeting held earlier today, all resolutions proposed were duly approved by shareholders:
| Total votes for | % of shares voted | Total votes against | % of shares voted | Total votes | Votes withheld |
Ordinary resolutions |
|
|
|
|
|
|
Resolution 1: To receive and adopt the report of the directors and the audited accounts of the Company for the period ended 31 December 2023 | 91,444,802 | 99.94 | 55,722 | 0.06 | 91,500,524 | - |
Resolution 2: To re-elect Simon Neicheril as a director of the Company | 91,426,718 | 99.94 | 54,753 | 0.06 | 91,481,471 | 19,053 |
Resolution 3: To re-elect Robert Fary as a director of the Company | 91,426,718 | 99.94 | 54,753 | 0.06 | 91,481,471 | 19,053 |
Resolution 4: To re-elect Paul Tuson as a director of the Company | 91,426,574 | 99.94 | 54,897 | 0.06 | 91,481,471 | 19,053 |
Resolution 5: To re-appoint Gerald Edelman LLP as auditor to the Company | 91,456,503 | 99.95 | 43,877 | 0.05 | 91,500,380 | 144 |
Resolution 6: To authorise the directors to determine the remuneration of the auditors | 91,442,594 | 99.96 | 38,877 | 0.04 | 91,481,471 | 19,053 |
Resolution 7: To grant the directors authority to allot shares pursuant to Section 551 of the Companies Act 2006 and grant rights to subscribe for, or convert any security into, shares | 91,439,344 | 99.93 | 61,180 | 0.07 | 91,500,524 | - |
Special resolutions | ||||||
Resolution 8: To dis-apply pre-emption rights pursuant to Section 570 of the Companies Act 2006 | 86,818,255 | 94.90 | 4,663,216 | 5.10 | 91,481,471 | 19,053 |
Resolution 9: To authorise the directors to make market purchases | 86,896,258 | 94.97 | 4,604,266 | 5.03 | 91,500,524 | - |
For further information please contact:
Belluscura plc | Tel: +44 (0)20 3128 8100 |
Adam Reynolds, Chairman Robert Rauker, Chief Executive Officer Simon Neicheril, Chief Financial Officer | |
SPARK Advisory Partners Limited (Nominated Adviser) | Tel: +44 (0)20 3368 3550 |
Neil Baldwin / Jade Bayat | |
Dowgate Capital Limited (Broker) | Tel: +44 (0)20 3903 7715 |
James Serjeant / Russell Cook | |
MHP Group (Financial PR & Investor Relations) | Tel: +44 (0)20 3128 8100 |
Katie Hunt / Matthew Taylor |
About Belluscura plc (https://belluscura.com/)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
Related Shares:
Belluscura